Betablocker Therapy in Pulmonary Arterial Hypertension

VU medical center0 个研究点开始时间: 2010年8月30日最近更新: 2012年3月19日

试验速览

暂无简介。

•Population:
•The VUMC serves as a national tertiary referral centre for the diagnosis and treatment of PAH and had 1500 referrals in 10 years. Currently more than 100 idiopathic PAH patients are treated in the VUMC, which make it possible to select our study population with care from this large cohort.
•We choose to limit our study to idiopathic PAH patients, since this is a well-characterized homogenous group with little or no co-morbidities. It is estimated that the current prevalence of iPAH in the Netherlands is about 200 patients. However, if our results turn out to be positive this might have an important impact on the management of other more common types of pulmonary hypertension.
•Inclusion criteria
•From our database containing currently 156 PAH patients we will carefully select patients who meet the following inclusion criteria:
•Idiopathic PAH patients
•Stable on PAH specific treatment defined
•oNo change in PAH specific treatment in the past 6 months
•oNo change in functional class in the past 6 months
•o<10 % change in 6 minute walk distance in the past 6 months
•Functional class 2 or 3
•In sinus rhythm
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Exclusion criteria are
•History of systemic hypertension, ischaemic heart disease, valvular disease or cardiomyopathy.
•Use of concomitant medication other than diuretics, Acenocoumarol and PAH targeted therapy
•History of cardiac arrhythmias or the use of anti-arrhythmic drugs
•Sick sinus syndrome
•systolic hypotension < 90 mmHg
•Clinically relevant sinus-bradycardia.

发起方

VU medical center